2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
Dawson N, Conaway M, Halabi S, Winer E, Small E, Lake D, Vogelzang N. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer 2000, 88: 825-834. PMID: 10679652, DOI: 10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaMegestrol acetateProstate carcinomaStable diseasePartial responsePerformance statusDay doseHigh-dose megestrol acetateEnd pointPossible dose-response effectDose megestrol acetateHigher baseline PSAOral megestrol acetateHigh-dose therapyPoor performance statusPrimary end pointSecondary end pointsMedian survival timeAdvanced prostate carcinomaDose-response effectDose-response correlationEvaluable diseaseMeasurable diseaseDose therapyBaseline PSA
1996
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Journal Of Infusional Chemotherapy 1996, 6: 211-6. PMID: 9229318.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSymptom Distress ScaleFunctional Living Index-CancerFirst-line settingFirst-line therapyBreast cancerContinuous infusionDisease progressionPrevious phase II studyRefractory metastatic breast cancerAdequate bone marrowContinuous infusion fluorouracilGrade 3 mucositisECOG performance statusMedian overall survivalObjective response ratePhase II studyContinuous intravenous infusionQuality of lifeEvaluable diseaseFLIC scoresInfusion fluorouracilMeasurable diseasePrior chemotherapyIndex cancer